celinehh94

I'm the Founder/CEO - appreciate the excitement! :) Lot's of work to do still, but a very important step for dogs and for lifespan extension pharmaceuticals.

Congrats Maddie & team!!!

hey dang, I'm the author. Thanks for cleaning everything up - I'm sometimes a bit nervous when my work gets posted on HN for what happened here. I really appreciate you & the HN team being so proactive in fixing it!

Hey! I’m the author. Biotech is not as well comp’ed, especially when you compare years of experience. For context, senior (Director, VP) levels make low to mid 200s, PhDs with work experience make mid 100s, and straight out of grad school make 80-120s

This doesn’t take into account equity, which most bio hires have zero context for and are easily taken advantage of when negotiating. I give equity packages in line with tech standards, but I could have cut them by 3-5X and still been competitive with the standard bio co.

Hi! I'm Celine - a little embarrassed this is trending because it is very much still a draft - please forgive any typos!

I hope this is helpful and always happy to chat biotech startups - just email me - celinehh.com/about

Sorry - should say use the valuation of the drug to determine patient access to it in the US. AKA, ICER could determine that drug 1 is massively un-cost-effective in comparison to drug 2, but you cannot restrict access to drug 1 due to this information. Most other countries tie drug price somewhat to health gain delivered by said drug.

Vaccines are actually super unprofitable for Pharma companies, so this isn't a great model to emulate (although I agree with the general metaphor of gene therapy -> vaccines)

https://www.nber.org/papers/w9833

Quick interesting note on this front - ICER is a US non-profit, but has basically zero influence in the actual pricing of drugs. It's actually illegal to value drugs this way in the US